Alkermes Shareholders Reject All of Sarissa's Nominees for Its Board
The biopharma company instead chose to re-elect its existing board members.
Stay updated with breaking news from Alkerme Board. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The biopharma company instead chose to re-elect its existing board members.
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) (the Company) today announced that, at the Company's 2023 Annual General Meeting of Shareholders (the Annual...
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) (the Company) today announced that independent shareholder advisory firm Institutional Shareholder Services (ISS)...
ALKS, $31.48, Market Capitalization: $5.2 billion), a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience ...
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) (the Company) today issued a letter to its shareholders in connection with the Company's upcoming 2023 Annual...